Open AccessAbstract CT111: Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Author(s) -
Laura Reyes-Uribe,
Wenhui Wu,
Ozkan Gelincik,
Prashant Bommi,
Alejandro FranciscoCruz,
Luisa M. Solis,
Patrick M. Lynch,
Ramona M. Lim,
Elena M. Stoffel,
Priyanka Kanth,
N. Jewel Samadder,
Maureen E. Mork,
Melissa W. Taggart,
Ginger L. Milne,
Lawrence J. Marnett,
Lana A. Vornik,
Diane D. Liu,
María V. Revuelta,
Kyle Chang,
Y. Nancy You,
Levy Kopelovich,
Ignacio I. Wistuba,
J. Jack Lee,
Shizuko Sei,
Robert H. Shoemaker,
Éva Szabó,
Ellen Richmond,
Asad Umar,
Marjorie Perloff,
Powell H. Brown,
Steven M. Lipkin,
Eduardo Vilar
Publication year - 2020
Publication title -
cancer research
Language(s) - Uncategorized
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct111
Subject(s) - medicine , tolerability , colorectal cancer , naproxen , placebo , gastroenterology , lynch syndrome , population , intestinal mucosa , irritable bowel syndrome , adverse effect , oncology , cancer , pathology , dna mismatch repair , alternative medicine , environmental health